Loading
EirGenix: what insiders have been doing
EirGenix is a listed company. Its directors and officers file their transactions with TWSE / TPEx (MOPS). Between 18 October 2025 and 18 October 2026, 9 insiders published 10 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
With 10 filings in twelve months, the company is more active than the median of 2 filings across the 515 companies we follow on the same exchange.
Insider buying of EirGenix has been absent for the past year. Publication is fast: at least half of the trades appear on TWSE / TPEx (MOPS) on the same day. Until a filing is published, the market cannot know about the trade.
Every figure here comes from the filings published by TWSE / TPEx (MOPS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
10
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 22,750 of 24,148 companies
17.0
score / 100
Value19
Quality15
FCF yld-9.2%
Earn yld-5.3%
EV/EBITDA·
ROE-7.0%
Gross mgn19%
Net mgn-76%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$48
Analyst consensus
1 analysts1.00/5
NT$111Target NT$111(+131%)NT$111
Income statement
RevenueNT$1B
Gross profitNT$193.8M19% margin
EBITDA-NT$505.5M-50% margin
Net income-NT$760.6M-46.9% margin
Valuation
PER (forward)84.5x
P/Book1.9x
Beta0.31
Balance sheet & cash
Market capNT$14.4B
Total debtNT$1.7B
Free Cash Flow-NT$1.3B
Debt / Equity22%
Profitability & ownership
ROE-7.0%
ROA-5.1%
% insiders33.7%
% institutions11.3%
Last declaration on 13 May 2026
Declarations10 total
10 of 10 declarations
About EirGenix
Taiwan Biotech is a company listed on the XTAI market, specializing in the biotechnology sector. It focuses on developing innovative products to enhance human health.